0.4304
-0.0399 (-8.48%)
-0.0399 (-8.48%)
Upgrade to Real-Time
Afterhours (Closed)
Volume | 67,084 |
|
|||||
News | - | ||||||
Day High | 0.486 | Low High |
|||||
Day Low | 0.4261 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Nymox Pharmaceutical Corp | NYMX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.476 | 0.4261 | 0.486 | 0.4304 | 0.470301 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
160 | 67,084 | $ 0.4415035 | $ 29,618 | - | 0.185 - 2.10 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:07:09 | formt | 1,595 | $ 0.4261 | USD |
Nymox Pharmaceutical Corp Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 38.96M | 90.52M | 42.96M | $ - | $ - | -0.15 | -4.70 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | - | 31.20% |
Nymox Pharmaceutical News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NYMX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.44 | 0.499 | 0.42 | 0.4446212 | 66,263 | -0.0096 | -2.18% |
1 Month | 0.4046 | 0.50 | 0.3901 | 0.4418464 | 54,168 | 0.0258 | 6.38% |
3 Months | 0.315 | 0.7427 | 0.2722 | 0.4476441 | 209,678 | 0.1154 | 36.63% |
6 Months | 0.38 | 0.7427 | 0.2722 | 0.4445163 | 148,030 | 0.0504 | 13.26% |
1 Year | 1.68 | 2.10 | 0.185 | 0.6386373 | 242,772 | -1.25 | -74.38% |
3 Years | 3.16 | 4.90 | 0.185 | 1.70 | 227,711 | -2.73 | -86.38% |
5 Years | 3.36 | 4.90 | 0.185 | 1.91 | 183,830 | -2.93 | -87.19% |
Nymox Pharmaceutical Description
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe. |